Chepe Nicoli /
3 November 2014AmericasJosé Trigueros

A changing landscape: approving biosimilar products in Mexico

A recent decision by the First Chamber of the Mexican Supreme Court of Justice on the granting of sanitary registrations, or health certificates, relating to Abbreviated New Drug Applications (ANDAs) for biosimilars or follow-on biologics in Mexico is beginning to change the legal landscape for both generic and innovative pharmaceutical companies in the country.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at